Miniderm Comp: Uses, Dosage & Side Effects
A topical combination cream containing lidocaine and urea for the relief of itching and treatment of dry, rough skin conditions
Miniderm Comp is a prescription topical cream that combines two active ingredients — lidocaine (2%) and urea (20%) — to provide both rapid itch relief and deep skin moisturization. Lidocaine is a well-established local anesthetic that numbs the skin by blocking nerve signal transmission, while urea at 20% concentration acts as a powerful humectant and keratolytic agent that draws moisture into the outer skin layer and softens dry, rough, or thickened skin. This dual-action formulation is prescribed for a range of dermatological conditions characterized by itching and dryness, including eczema, xerosis (severe dry skin), ichthyosis, and other pruritic dermatoses. The cream is applied directly to the affected skin area and is generally well tolerated, with mild local reactions such as temporary stinging being the most commonly reported side effects.
Quick Facts: Miniderm Comp
Key Takeaways
- Miniderm Comp combines lidocaine (2%) for rapid itch and pain relief with urea (20%) for deep moisturization and keratolytic action, making it a dual-purpose treatment for itchy, dry skin conditions.
- The cream is typically applied 2–3 times daily to affected areas and provides itch relief within 5–15 minutes, while the moisturizing effects of urea build progressively over 1–2 weeks of regular use.
- Common side effects are mild and localized, primarily consisting of transient stinging or burning at the application site, which is more noticeable on cracked or fissured skin and decreases with continued use.
- Do not apply Miniderm Comp to broken skin, open wounds, infected skin, or mucous membranes, and avoid contact with the eyes. The cream is for external use only.
- Store at room temperature below 25°C, and do not use after the expiration date. The tube should be used within 6 months of first opening.
What Is Miniderm Comp and What Is It Used For?
Miniderm Comp is a combination topical cream that contains two well-characterized active pharmaceutical ingredients: lidocaine hydrochloride at a concentration of 20 mg/g (2%) and urea at 200 mg/g (20%). These two substances work through entirely different but complementary pharmacological mechanisms, making the combination particularly effective for skin conditions where both symptom relief (itching, discomfort) and skin barrier restoration (hydration, removal of dead skin) are therapeutic goals.
Lidocaine is one of the most widely used local anesthetics in medicine, listed on the World Health Organization’s Model List of Essential Medicines. It belongs to the amide class of local anesthetics and works by reversibly blocking voltage-gated sodium channels in the nerve cell membrane. When applied topically to the skin, lidocaine penetrates the stratum corneum and reaches the superficial nerve endings in the epidermis and upper dermis. By blocking sodium channel conduction, it prevents the initiation and propagation of nerve impulses responsible for transmitting itch (pruritus) and pain signals from the skin to the central nervous system. The onset of action is typically within 5 to 15 minutes of application, and the duration of the anesthetic effect can last from 1 to 3 hours depending on the thickness of the skin and the area treated.
Urea, also known as carbamide, is a naturally occurring substance in the human body and is one of the key components of the skin’s natural moisturizing factor (NMF). The NMF is a complex mixture of water-soluble compounds found within corneocytes (the cells of the outermost skin layer, the stratum corneum) that are critical for maintaining skin hydration and barrier function. At concentrations of 10–20%, urea acts as both a potent humectant and a mild keratolytic agent. As a humectant, urea draws water from the deeper layers of the skin (dermis) into the stratum corneum, increasing hydration and improving skin flexibility. As a keratolytic, it disrupts hydrogen bonds between keratin molecules in the stratum corneum, facilitating the shedding of dead, dry, and thickened skin cells. This dual action results in smoother, softer, and better-hydrated skin.
Additionally, urea at 20% concentration has been shown to enhance the percutaneous absorption of other topically applied substances by disrupting the tightly packed lipid-corneocyte structure of the stratum corneum. In the context of Miniderm Comp, this means that urea may enhance the penetration and local bioavailability of lidocaine, potentially improving its anesthetic efficacy at the site of application. This pharmacokinetic synergy is one of the rationales for combining these two active ingredients in a single formulation.
Miniderm Comp is indicated for the symptomatic treatment of a range of dermatological conditions characterized by itching and dryness. These include:
- Eczema (atopic dermatitis): A chronic inflammatory skin condition characterized by dry, itchy, and inflamed skin. Miniderm Comp can provide relief from the persistent itch that is often the most distressing symptom, while simultaneously addressing the underlying skin barrier dysfunction through urea’s moisturizing action.
- Xerosis (severe dry skin): Clinically significant skin dryness that goes beyond normal dry skin, often occurring in elderly patients, during winter months, or as a side effect of certain medications. The 20% urea component is particularly effective for this condition.
- Ichthyosis: A group of genetic skin disorders characterized by thick, dry, scaly skin. Urea at 20% is a first-line keratolytic treatment for ichthyosis, and the addition of lidocaine provides relief from associated discomfort and itching.
- Pruritus of various origins: Itching that may be associated with dermatitis, insect bites, minor skin irritations, or systemic conditions. Lidocaine provides rapid symptomatic relief while the underlying cause is addressed.
- Hyperkeratotic conditions: Conditions involving thickened, rough skin areas where the keratolytic action of urea helps soften and remove the excess keratinized tissue.
The cream formulation provides a balanced base that is easy to spread, absorbs reasonably well into the skin, and leaves a protective moisturizing layer. The vehicle (cream base) typically contains emollients, emulsifiers, and preservatives that contribute to the overall moisturizing and skin-conditioning properties of the product. Miniderm Comp is designed for regular use as part of a comprehensive skin care regimen and can be used alongside other dermatological treatments as directed by a healthcare provider.
Many patients with dry, itchy skin conditions require both symptom relief and skin barrier repair. By combining lidocaine and urea in a single cream, Miniderm Comp addresses both needs simultaneously, improving patient compliance by reducing the number of separate products that need to be applied. The urea component may also enhance the penetration of lidocaine, potentially making the anesthetic effect more consistent and effective.
What Should You Know Before Using Miniderm Comp?
Contraindications
Miniderm Comp must not be used if you are hypersensitive (allergic) to lidocaine, other local anesthetics of the amide type (such as bupivacaine, mepivacaine, or prilocaine), urea, or any of the other ingredients listed in the cream’s composition. Allergic contact dermatitis to amide-type local anesthetics is uncommon but has been documented in the medical literature. If you have previously experienced an allergic reaction to any local anesthetic product, inform your doctor before using Miniderm Comp.
The cream must not be applied to broken, damaged, or actively infected skin. Application of lidocaine to compromised skin barriers can result in increased systemic absorption, raising the risk of lidocaine toxicity. Similarly, applying the cream to infected skin can worsen the infection by creating a moist, occlusive environment and potentially introducing the cream’s components into the wound. Mucous membranes (including the mouth, nostrils, genital area, and rectal area) should also be avoided, as absorption through these tissues is significantly higher than through intact skin.
The cream should not be applied to or near the eyes. If accidental contact with the eyes occurs, rinse immediately with plenty of clean water and seek medical attention if irritation persists.
Warnings and Precautions
Miniderm Comp is for application to intact skin only. Do not apply to open wounds, burns, infected skin, or mucous membranes. If you accidentally ingest the cream or it comes into contact with the eyes, seek medical advice immediately. Excessive application to large body surface areas or use under occlusive dressings may increase the risk of systemic lidocaine absorption.
Before using Miniderm Comp, discuss the following considerations with your healthcare provider:
- Large area application: If you need to apply the cream to extensive areas of skin, be aware that this increases the total amount of lidocaine absorbed systemically. Your doctor may need to limit the area of application or the frequency of use to prevent systemic effects of lidocaine, which can include dizziness, drowsiness, numbness of the tongue, metallic taste, or in rare cases, more serious cardiovascular or neurological effects.
- Occlusive dressings: Covering the treated area with airtight (occlusive) dressings or bandages can significantly increase the absorption of both lidocaine and urea through the skin. Do not use occlusive dressings over Miniderm Comp unless specifically instructed by your doctor.
- Sensitivity in thin-skinned areas: The face, groin, axillae (armpits), and skin folds have thinner skin with higher permeability. Application to these areas may result in increased drug absorption and a higher likelihood of local irritation. Use with caution and as directed.
- Liver disease: Lidocaine is primarily metabolized in the liver by cytochrome P450 enzymes (CYP1A2 and CYP3A4). Patients with severe hepatic impairment may have reduced ability to metabolize absorbed lidocaine, increasing the risk of accumulation and systemic toxicity with prolonged use over large areas. Your doctor may recommend monitoring or dose adjustment.
- Cardiac conditions: Patients with severe heart disease, heart block, or a history of cardiac arrhythmias should use Miniderm Comp with caution, particularly if applying it to large skin areas. Although systemic absorption from topical application is generally low, lidocaine at higher systemic concentrations can affect cardiac conduction.
Pregnancy and Breastfeeding
If you are pregnant, think you may be pregnant, or are planning to become pregnant, consult your doctor before using Miniderm Comp. Lidocaine is known to cross the placental barrier; however, the amount absorbed systemically from topical application to intact skin is generally very low. Animal reproductive studies with lidocaine have not demonstrated clear evidence of harm to the fetus, and lidocaine has been widely used in various formulations during pregnancy (including dental procedures and epidural anesthesia) without significant reports of adverse fetal effects. Urea is a naturally occurring substance in the body and is considered safe for topical use during pregnancy.
Nevertheless, as a general precaution, it is advisable to use Miniderm Comp during pregnancy only if the expected benefit justifies any potential risk, and to minimize the area of application and duration of treatment. Avoid applying the cream to large body surface areas during pregnancy.
Lidocaine is excreted in human breast milk in small quantities. However, the amount reaching breast milk from topical skin application is expected to be extremely low and unlikely to affect the nursing infant. Urea is a normal component of the body and poses no risk through breast milk. If you are breastfeeding, you may use Miniderm Comp as directed, but avoid applying the cream to the breast area or any area that may come into direct contact with the infant’s mouth.
Use in Children
Miniderm Comp may be used in children under medical supervision, but special caution is warranted. Children, particularly infants and young children, have a higher ratio of body surface area to body weight compared to adults, and their skin is generally thinner and more permeable. This can result in proportionally greater systemic absorption of lidocaine following topical application. Your pediatrician or pediatric dermatologist will determine the appropriate area of application and frequency based on your child’s age, weight, and the extent of the skin condition. Do not exceed the recommended dose or area of application in children.
Use in Elderly Patients
Elderly patients often present with xerosis (age-related dry skin) that may benefit significantly from the urea component of Miniderm Comp. No specific dose adjustment is generally required for elderly patients. However, elderly individuals may have thinner skin, reduced hepatic function, or concurrent use of multiple medications, all of which could increase the risk of lidocaine-related side effects. Monitor for any unusual symptoms and consult your healthcare provider if concerns arise.
How Does Miniderm Comp Interact with Other Drugs?
Because Miniderm Comp is applied topically and the systemic absorption of lidocaine through intact skin is generally low, the risk of clinically significant drug interactions is considerably lower than with oral or injectable medications. However, certain interactions deserve attention, particularly in patients applying the cream over large body areas, using occlusive dressings, or who have compromised skin barriers.
The following table summarizes the key drug interaction considerations for Miniderm Comp:
| Drug / Drug Class | Interaction Type | Clinical Significance | Recommendation |
|---|---|---|---|
| Other topical local anesthetics (e.g., EMLA, lidocaine patches) | Additive lidocaine exposure | Moderate | Avoid concurrent use on overlapping areas; monitor total lidocaine dose |
| Class I antiarrhythmics (mexiletine, tocainide, flecainide) | Additive cardiac conduction effects | Low to moderate (with large area application) | Use with caution; avoid large area application |
| Class III antiarrhythmics (amiodarone, sotalol) | Additive cardiac effects | Low to moderate (with large area application) | Use with caution; consult cardiologist if concerned |
| CYP1A2 inhibitors (fluvoxamine, ciprofloxacin) | Reduced lidocaine metabolism | Low (minimal systemic absorption) | Generally no action needed; caution with large area use |
| CYP3A4 inhibitors (ketoconazole, erythromycin) | Reduced lidocaine metabolism | Low (minimal systemic absorption) | Generally no action needed; caution with large area use |
| Beta-blockers (propranolol, metoprolol) | Reduced lidocaine clearance | Low (minimal systemic absorption) | No adjustment typically needed |
| Other topical medications (corticosteroids, emollients) | Possible altered absorption | Low | Space applications 15–30 minutes apart if using multiple topicals |
It is important to emphasize that the clinical significance of most of these interactions is low when Miniderm Comp is used as directed on limited skin areas with intact skin barrier. The interactions become more relevant when the cream is applied to large body surface areas, under occlusive dressings, or when the skin barrier is significantly compromised (e.g., in severe eczema with extensive fissuring), all of which can increase systemic lidocaine absorption.
Urea, the other active ingredient in Miniderm Comp, does not have any known drug interactions. As a naturally occurring metabolic product present at high concentrations throughout the body, it does not interact with drug metabolism enzymes or transport systems. However, urea’s keratolytic effect on the stratum corneum may theoretically enhance the percutaneous penetration of other topically applied drugs. For this reason, if you are using multiple topical medications on the same skin area, it is generally advisable to space the applications by at least 15 to 30 minutes and to inform your doctor about all topical treatments you are using.
Always inform your doctor or pharmacist about all medications you are taking, including prescription drugs, over-the-counter products, herbal supplements, and other topical preparations. This helps ensure that your treatment regimen is safe and optimally effective.
If you use Miniderm Comp alongside other topical treatments (such as corticosteroid creams or emollients), apply each product at least 15–30 minutes apart to allow adequate absorption and minimize interactions. As a general rule, apply the thinnest consistency first (lotions before creams, creams before ointments). Your dermatologist can advise on the optimal order and timing for your specific treatment regimen.
What Is the Correct Dosage of Miniderm Comp?
Miniderm Comp should always be used exactly as your doctor or pharmacist has instructed. The cream is applied topically (to the skin surface) and is not intended for oral, rectal, vaginal, or ophthalmic use. The correct dosage depends on the extent and severity of the skin condition, the age of the patient, and the body area being treated.
Adults
Standard Adult Dosage
Apply a thin layer of Miniderm Comp to the affected area 2–3 times daily. Gently massage the cream into the skin until it is absorbed. The amount used should be sufficient to cover the affected area with a thin film — as a general guide, a fingertip unit (approximately 0.5 g, the amount squeezed from a tube along the length of an adult fingertip from crease to tip) covers an area roughly equivalent to two adult palms.
The general principles for topical application include:
- Clean skin: Apply the cream to clean, dry skin. If the area has been washed, allow it to dry gently (pat dry rather than rubbing) before application.
- Thin layer: A thin, even layer is sufficient. Using excessive amounts does not increase efficacy but may increase the risk of local irritation and systemic absorption.
- Gentle massage: Gently rub the cream into the skin in a circular motion until it is no longer visible on the surface. This aids absorption and distributes the active ingredients evenly.
- Hand washing: Wash your hands thoroughly after applying the cream, unless the hands are the treatment area. This prevents inadvertent transfer of lidocaine to the eyes, mouth, or other sensitive areas.
- Avoid face and genitals: Unless specifically directed by your doctor, avoid applying Miniderm Comp to the face, genitals, or skin folds where increased absorption may occur.
Children
Pediatric Dosage
The dosage for children is determined by the treating physician based on the child’s age, weight, and the extent of the affected area. As a general guideline, the area of application and frequency should be proportionally reduced compared to adults. Do not apply to more than 10% of body surface area in children without medical supervision. Use the minimum effective amount for the shortest duration necessary.
Children have proportionally greater skin surface area relative to body weight and thinner skin, resulting in higher potential for systemic absorption of lidocaine. Close monitoring is advisable, particularly in infants and young children. Signs of systemic lidocaine toxicity in children include unusual drowsiness, restlessness, blurred vision, or numbness around the mouth. If any of these symptoms occur, discontinue use and seek immediate medical attention.
Elderly
No specific dose adjustment is required for elderly patients. However, elderly individuals often have thinner, more fragile skin with reduced barrier function, which may lead to increased absorption. Additionally, hepatic blood flow and enzyme activity may be reduced in elderly patients, potentially slowing the metabolism of any absorbed lidocaine. It is prudent to start with smaller application areas and to monitor for any adverse effects, particularly during the first week of treatment.
Missed Dose
If you forget to apply Miniderm Comp at the scheduled time, apply it as soon as you remember. If it is almost time for your next application, skip the missed dose and continue with your regular schedule. Do not apply a double amount to compensate for a missed application. Miniderm Comp works best with regular, consistent use, so establishing a routine (such as applying the cream after your morning shower and before bedtime) can help maintain consistency.
Overdose
Topical overdose (applying excessive amounts or applying to very large body areas) is unlikely to cause serious systemic effects in most circumstances. However, if an unusually large amount of cream has been applied, particularly on broken or inflamed skin, or if the cream is accidentally ingested, symptoms of lidocaine toxicity may occur. Early symptoms of systemic lidocaine toxicity include:
- Numbness or tingling of the tongue and lips
- Metallic taste in the mouth
- Lightheadedness or dizziness
- Drowsiness or restlessness
- Blurred or double vision
- Ringing in the ears (tinnitus)
In severe cases (which are extremely rare with topical use), more serious symptoms can include tremors, seizures, respiratory depression, and cardiac arrhythmias. If you suspect an overdose or experience any of these symptoms, remove any remaining cream from the skin with a cloth, wash the area with soap and water, and seek immediate medical attention. If the cream has been accidentally swallowed, contact a poison control center or emergency department immediately.
If Miniderm Comp is accidentally swallowed, seek medical attention immediately. Lidocaine ingestion can cause numbness of the mouth and throat, nausea, vomiting, and in larger amounts, more serious systemic effects. Keep this and all medications out of reach of children.
What Are the Side Effects of Miniderm Comp?
Like all medicines, Miniderm Comp can cause side effects, although not everybody gets them. The side effects are predominantly local (at the site of application) and are generally mild and self-limiting. Serious systemic side effects are very rare when the cream is used as directed on intact skin of limited area.
The following side effects have been reported with the use of lidocaine and/or urea-containing topical preparations:
Very Common (may affect more than 1 in 10 people)
Frequency: >1/10
- Transient stinging or burning sensation at the application site (particularly when applied to dry, fissured, or cracked skin; this typically diminishes with continued use as the skin becomes more hydrated)
Common (may affect up to 1 in 10 people)
Frequency: 1/100 to 1/10
- Mild redness (erythema) at the application site
- Mild skin irritation or itching at the application site
- Skin dryness or tightness sensation (initially, before urea’s moisturizing effect develops)
Uncommon (may affect up to 1 in 100 people)
Frequency: 1/1,000 to 1/100
- Allergic contact dermatitis (rash, swelling, or blistering at the application site)
- Local skin pallor (whitening) due to lidocaine’s vasoconstrictive effect
- Mild numbness persisting beyond the expected duration
- Local skin peeling or flaking (as urea accelerates removal of dead skin cells)
Rare (may affect up to 1 in 1,000 people)
Frequency: <1/1,000
- Systemic lidocaine effects (dizziness, lightheadedness, drowsiness, metallic taste) — typically only with extensive application or use under occlusive dressings
- Urticaria (hives) or generalized allergic reaction
- Localized edema (swelling) at the application site
Not Known (frequency cannot be estimated from available data)
Frequency: Not known
- Anaphylactic reaction (extremely rare; seek immediate emergency medical attention if you experience difficulty breathing, swelling of the face, lips, tongue, or throat, or sudden severe dizziness)
- Cardiac arrhythmias or seizures (only with significant systemic absorption from very large area application or ingestion)
The transient stinging associated with urea is the most commonly encountered side effect and is a well-known pharmacological property of high-concentration urea preparations rather than an adverse drug reaction in the traditional sense. It occurs because urea is a small, osmotically active molecule that temporarily draws water within the damaged stratum corneum, stimulating superficial nerve endings. This effect is most pronounced on skin that is dry, cracked, or fissured, and characteristically diminishes over the first few days of treatment as the skin becomes more hydrated and the barrier function improves. Applying the cream to skin that has been recently washed and is slightly damp can help reduce the initial stinging sensation.
If you experience a rash, persistent irritation, swelling, or blistering at the application site, discontinue use and consult your doctor, as these may indicate an allergic contact dermatitis to lidocaine, urea, or one of the excipients in the cream base. Your doctor may arrange patch testing to identify the specific allergen.
If you notice any side effects not listed in this information, or if any side effects become serious, please tell your doctor or pharmacist. You can also report side effects directly to your national pharmacovigilance authority to help provide more information about the safety of this medicine.
Contact your doctor immediately if you experience: signs of a serious allergic reaction (difficulty breathing, swelling of the face or throat, severe rash or hives), dizziness or drowsiness after application, irregular heartbeat, or visual disturbances. These may indicate significant systemic lidocaine absorption and require medical evaluation.
How Should You Store Miniderm Comp?
Proper storage of Miniderm Comp is important to maintain the stability and efficacy of both active ingredients and to ensure the cream remains safe to use throughout its shelf life. The following storage conditions should be observed:
- Temperature: Store at room temperature, below 25°C (77°F). Avoid exposure to excessive heat, as high temperatures can alter the consistency of the cream base, potentially affecting the uniform distribution of active ingredients and the texture of the product.
- Freezing: Do not freeze the cream. Freezing can break the emulsion (the mixture of oil and water phases in the cream base), resulting in phase separation, changed consistency, and reduced efficacy. If the cream has been accidentally frozen, do not use it — dispose of it properly and obtain a new tube.
- Light: Store in the original packaging to protect from light. While neither lidocaine nor urea is particularly photosensitive, the overall formulation may degrade more rapidly if exposed to prolonged direct sunlight or intense artificial light.
- Moisture: Keep the tube tightly closed when not in use to prevent contamination and to maintain the moisture content of the cream. Leaving the cap off can lead to drying out of the cream at the opening and potential microbial contamination.
- After opening: Once the tube has been opened, the cream should generally be used within 6 months, or as stated on the packaging. After this period, the preservative system may not adequately protect against microbial growth.
- Expiration date: Do not use the cream after the expiration date (EXP) printed on the tube and outer packaging. The expiration date refers to the last day of that month.
- Children: Keep out of the sight and reach of children. Store in a location that is not accessible to young children to prevent accidental ingestion or misuse.
Do not dispose of medications via wastewater or household waste. Ask your pharmacist about the proper way to dispose of medicines that are no longer needed. These measures help protect the environment and prevent accidental exposure.
If you notice any change in the appearance of the cream — such as a change in color, consistency, or odor — do not use it and consult your pharmacist. These changes may indicate degradation of the product or microbial contamination.
What Does Miniderm Comp Contain?
Active Ingredients
Each gram of Miniderm Comp cream contains:
| Ingredient | Concentration | Role | Mechanism |
|---|---|---|---|
| Lidocaine (as hydrochloride) | 20 mg/g (2%) | Local anesthetic | Blocks sodium channels in nerve endings to prevent itch and pain signal transmission |
| Urea (Carbamide) | 200 mg/g (20%) | Keratolytic & Humectant | Draws moisture into the stratum corneum and disrupts hydrogen bonds in keratin to soften and hydrate dry skin |
Inactive Ingredients (Excipients)
The cream base typically contains a combination of inactive ingredients that serve various functions in the formulation, including maintaining stability, providing a pleasant texture, ensuring even distribution of the active ingredients, and preserving the product against microbial contamination. Common excipients in topical cream formulations like Miniderm Comp may include:
- Cetostearyl alcohol: An emulsifying and stabilizing agent that helps maintain the oil-in-water cream emulsion and gives the cream a smooth consistency.
- Macrogol cetostearyl ether: A non-ionic emulsifier that helps stabilize the cream formulation and improve its spreadability on the skin.
- Liquid paraffin: A mineral oil-based emollient that provides an occlusive barrier on the skin, reducing transepidermal water loss and contributing to the moisturizing effect.
- White soft paraffin (petrolatum): A semi-solid emollient that seals moisture into the skin and provides a protective barrier.
- Propylene glycol: A humectant and solvent that aids in the dissolution of active ingredients and contributes to skin hydration. Note: propylene glycol may cause skin irritation in some individuals.
- Preservatives: The formulation typically contains preservatives to maintain microbiological quality throughout the product’s shelf life.
- Purified water: The primary vehicle for the cream, providing the aqueous phase of the emulsion.
If you have known allergies or sensitivities to any excipients commonly used in topical formulations (particularly cetostearyl alcohol or propylene glycol, which are among the more common sensitizers in topical products), review the full ingredient list on the product packaging or patient information leaflet, and discuss any concerns with your pharmacist or doctor before use.
The cream is a white to off-white, smooth, homogeneous preparation with a faint characteristic odor. It is available in aluminum tubes with plastic screw caps. The typical pack sizes include 100 g tubes, although availability may vary by region.
Frequently Asked Questions About Miniderm Comp
Miniderm Comp is a prescription topical cream used to relieve itching and dryness associated with various skin conditions. It combines lidocaine (a local anesthetic that numbs itching and pain) with urea at 20% concentration (a potent moisturizer and keratolytic agent). It is commonly prescribed for eczema-related itch, xerosis (extremely dry skin), ichthyosis, pruritus of various origins, and hyperkeratotic skin conditions where both symptom relief and deep hydration are needed.
Apply a thin layer of Miniderm Comp cream to the affected area of skin 2–3 times daily, or as directed by your doctor. Gently massage the cream into the skin until absorbed. Wash your hands thoroughly after application unless the hands are being treated. Do not apply the cream to broken skin, open wounds, infected areas, or mucous membranes. Do not cover the treated area with occlusive dressings unless specifically instructed by your doctor.
Miniderm Comp should be used during pregnancy only if the potential benefit justifies the potential risk. Lidocaine can cross the placenta, although systemic absorption from topical application is generally very low. Urea is considered safe for topical use during pregnancy. As a precaution, avoid applying the cream to large areas of skin or under occlusive dressings during pregnancy. Always consult your doctor or midwife before using any medication during pregnancy or while breastfeeding.
The most common side effects are local skin reactions at the application site, including mild burning or stinging sensation (especially when applied to very dry or cracked skin), temporary redness (erythema), and mild irritation. These reactions are usually transient and subside within minutes. The stinging from urea is more pronounced on broken or fissured skin and typically decreases with continued use as the skin becomes more hydrated. Serious systemic side effects are very rare with topical application.
Miniderm Comp can be used in children, but only under medical supervision and as directed by a doctor. Children have thinner, more permeable skin, which may lead to increased absorption of lidocaine. The dosage and application area should be adjusted based on the child’s age, weight, and the extent of the skin condition. Do not apply to more than 10% of body surface area in children without medical supervision. Contact your pediatrician or dermatologist for specific guidance.
The itch-relieving effect of lidocaine typically begins within 5–15 minutes of application and can last for 1–3 hours. The moisturizing and keratolytic effects of urea develop more gradually over days to weeks of regular use, as the skin barrier is progressively restored. Most patients notice significant improvement in skin hydration and texture within 1–2 weeks of consistent application. For best results, continue using the cream as directed even after symptoms improve.
References
- World Health Organization (WHO). WHO Model List of Essential Medicines — 23rd List. Geneva: WHO; 2023. Lidocaine listed as essential medicine for local anesthesia.
- British Association of Dermatologists (BAD). Guidelines for the Management of Atopic Eczema (Atopic Dermatitis) in Adults and Children. British Journal of Dermatology. 2024.
- American Academy of Dermatology (AAD). Guidelines of Care for the Management of Atopic Dermatitis: Topical Therapies. Journal of the American Academy of Dermatology. 2024.
- Pan M, Heinecke G, Bernardo S, Tsui C, Levitt J. Urea: a comprehensive review of the clinical literature. Dermatology Online Journal. 2013;19(11):20392.
- Celleno L. Topical urea in skincare: A review. Dermatologic Therapy. 2018;31(6):e12690.
- European Medicines Agency (EMA). Guideline on the pharmacokinetic and clinical evaluation of modified-release dosage forms. EMA/CPMP/EWP/280/96 Corr1. 2023.
- Becker DE, Reed KL. Local Anesthetics: Review of Pharmacological Considerations. Anesthesia Progress. 2012;59(2):90–102.
- Loden M. Role of Topical Emollients and Moisturizers in the Treatment of Dry Skin Barrier Disorders. American Journal of Clinical Dermatology. 2003;4(11):771–788.
- Tadicherla S, Ross K, Shenefelt PD, Fenske NA. Topical corticosteroids in dermatology. Journal of Drugs in Dermatology. 2009;8(12):1093–1105.
- National Institute for Health and Care Excellence (NICE). Atopic eczema in under 12s: diagnosis and management. NICE Guideline CG57. Updated 2023.
Editorial Team
Medical Content
iMedic Medical Editorial Team — Specialists in Dermatology and Clinical Pharmacology
Medical Review
iMedic Medical Review Board — Independent panel reviewing content against international guidelines
Evidence Standard
GRADE Framework — Systematic assessment of evidence quality and strength of recommendations
Editorial Independence
No commercial funding — No pharmaceutical sponsorship or advertising influence
This article was written by our medical editorial team and reviewed by board-certified specialists in dermatology and clinical pharmacology. All information is based on peer-reviewed scientific literature, international clinical guidelines (WHO, BAD, AAD, NICE), and official product information. Our content follows the GRADE evidence framework and is free from commercial influence. Last medical review: .